uniQure CEO Matthew Kapusta Buys Shares of QURE

Matthew Kapusta, the CEO and Managing Director of uniQure N.V. (NasdaqGS:QURE), recently made a significant purchase of company shares. On June 18, 2026, Kapusta bought 4,656 shares at an average price of $31.71 each, amounting to a total transaction value of $147,641.76. This purchase was not part of a pre-planned trading program.

Insider Buying and Selling at uniQure N.V.

Kapusta's recent buy on June 18 wasn't his only transaction. He also sold 41,671 shares at $50 each on the same day as part of a planned sale. Additionally, another insider, Madhavan Balachandran, made transactions on June 17, buying 11,685 shares at $24.97 and selling the same amount at $45.06 under a planned sale.

Other Institutional Activity in uniQure

Several institutional investors have been active in uniQure recently. AVORO Capital Advisors LLC reduced its holdings by 190,405 shares, bringing its total to approximately 5.96 million shares worth $97.44 million, marking a 3.1% decrease. On the other hand, Aberdeen Group PLC increased its stake by 1,627,746 shares to a total of about 5.31 million shares, valued at $86.76 million, representing a 44.2% increase. JPMorgan Chase & Co cut its position by 97,160 shares, now holding approximately 2.84 million shares worth $41.80 million, a 3.3% decrease. Meanwhile, Two Sigma Investments, LP significantly increased its position by 1,224,587 shares, ending with about 2.68 million shares valued at $43.75 million, an 84.4% increase.

uniQure N.V. Stock Down 6.1%

Shares of uniQure traded near $46.37 on Monday. The company has a market cap of approximately $2.92 billion and a beta of 1.001, indicating moderate volatility. Over the past year, the stock has ranged from $8.73 to $71.50. It has a 50-day moving average of $24.13 and a 200-day moving average of $27.53. The current ratio stands at 10.40, and the quick ratio is 9.97, reflecting strong liquidity. However, its debt-to-equity ratio is high at 365.37.

Analysts Set New Price Targets

On June 18, 2026, Barclays upgraded uniQure's rating to 'buy' with a price target of $65. Goldman Sachs maintained its 'hold' rating with a $46 target, while Leerink Partners and RBC Capital both maintained 'buy' ratings with targets of $70 and $65, respectively. The consensus among analysts is a 'strong buy', with an average target price of $58.75 across 11 opinions.

About uniQure

uniQure N.V., based in Amsterdam, Netherlands, is a biotechnology company that develops treatments for rare and devastating diseases. Its flagship product, HEMGENIX, helps patients with hemophilia B. The company is also advancing several gene therapy candidates, including AMT-130 for Huntington's disease and AMT-260 for epilepsy. Founded in 1998, uniQure has a workforce of 221 employees.

Bottom Line

Matthew Kapusta's recent purchase of uniQure shares adds an interesting dynamic to the company's insider activity. Investors often track such moves for potential insights into future company performance. However, it's important to remember that insider purchases can be motivated by various factors. As always, 13F filings and insider transactions reflect past actions and may not indicate current positions.